Payment overview · 2025
General Payments
$820.81
28 reported records · 6 companies
Healthcare provider profile · identity verified
Dariusz Grabowski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · BROOKLYN, NY · NPI 1013082254
Verified facts
What the public records show
CMS Open Payments records show Dariusz Grabowski, M.D. received $820.81 in general payments during 2025 across 28 reported records.
Gilead Sciences, Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Biktarvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $173.04 | 21.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $157.42 | 19.2% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $154.05 | 18.8% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.24 | 18.3% | 6 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $124.91 | 15.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.15 | 7.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $820.81 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $138.99 | 6 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $124.91 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $95.99 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.53 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.15 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $58.06 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 281 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 67 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 633 | 175 |
| Omeprazole | Omeprazole | 561 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 514 | 129 |
| Fluticasone Propionate | Fluticasone Propionate | 430 | 133 |
| Ezetimibe | Ezetimibe | 427 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 366 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 324 | 78 |
| Losartan Potassium | Losartan Potassium | 322 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 303 | 75 |
| Baclofen | Baclofen | 300 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 106 |
| Eliquis | Apixaban | 281 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 73 |
| Gabapentin | Gabapentin | 257 | 66 |
| Mirtazapine | Mirtazapine | 221 | 44 |
| Furosemide | Furosemide | 214 | 49 |
| Metformin Hcl | Metformin Hcl | 214 | 54 |
| Alendronate Sodium | Alendronate Sodium | 210 | 41 |
| Lisinopril | Lisinopril | 179 | 49 |
| Famotidine | Famotidine | 162 | 48 |
| Simvastatin | Simvastatin | 160 | 40 |
| Atenolol | Atenolol | 157 | 42 |
| Azelastine Hcl | Azelastine Hcl | 153 | 37 |
| Lovastatin | Lovastatin | 144 | 40 |
| Finasteride | Finasteride | 142 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 28 |
| Glimepiride | Glimepiride | 131 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 126 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 33 |
| Jardiance | Empagliflozin | 125 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 118 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 21 |
| Allopurinol | Allopurinol | 116 | 24 |
| Sertraline Hcl | Sertraline Hcl | 113 | 28 |
| Enalapril Maleate | Enalapril Maleate | 107 | 23 |
| Montelukast Sodium | Montelukast Sodium | 101 | 25 |
| Ozempic | Semaglutide | 94 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 31 |
| Metformin Hcl Er | Metformin Hcl | 92 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 25 |
| Meclizine Hcl | Meclizine Hcl | 90 | 33 |
| Potassium Chloride | Potassium Chloride | 88 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 18 |
| Hydrocortisone | Hydrocortisone | 81 | 26 |
| Farxiga | Dapagliflozin Propanediol | 76 | 20 |
| Lidocaine | Lidocaine | 70 | 26 |
| Mupirocin | Mupirocin | 70 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 19 |
| Celecoxib | Celecoxib | 68 | 22 |
| Trulicity | Dulaglutide | 68 | 12 |
| Bupropion Xl | Bupropion Hcl | 66 | 15 |
| Januvia | Sitagliptin Phosphate | 66 | 13 |
| Ketoconazole | Ketoconazole | 65 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 19 |
| Valacyclovir | Valacyclovir Hcl | 60 | 20 |
| Carvedilol | Carvedilol | 59 | 21 |
| Trazodone Hcl | Trazodone Hcl | 59 | 12 |
| Xarelto | Rivaroxaban | 57 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | 13 |
| Lactulose | Lactulose | 56 | 18 |
| Vascepa | Icosapent Ethyl | 56 | 13 |
| Chlorthalidone | Chlorthalidone | 55 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 16 |
| Meloxicam | Meloxicam | 51 | 16 |
| Valsartan | Valsartan | 51 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 13 |
| Prednisone | Prednisone | 47 | 24 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Myrbetriq | Mirabegron | 45 | 14 |
| Ammonium Lactate | Ammonium Lactate | 44 | 15 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 13 |
| Nitroglycerin | Nitroglycerin | 42 | 21 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | 11 |
| Indapamide | Indapamide | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Cefdinir | Cefdinir | 30 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 14 |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Folic Acid | Folic Acid | 28 | 11 |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Naproxen | Naproxen | 25 | 13 |
| Telmisartan | Telmisartan | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Enulose | Lactulose | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Combipatch | Estradiol/Norethindrone Acet | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $820.81 · 28 records | Gilead Sciences, Inc. | AIRSUPRA, BREZTRI, CAMZYOS, CAPVAXIVE, Cologuard Collection Kit, DOVATO, ELIQUIS, FARXIGA, GARDASIL 9, VERQUVO, Yeztugo | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error